Wild type cells (first lane) or just transduced with the Renilla construct (second lane) had no firefly signal. In the reporter cells induction of the promoter and firefly reporter expression increased over the time meanwhile Renilla signal is not affected by interferon induction and is only depending on cell number and viability. Viability (Renilla signal) and reporter expression (firefly bioluminescence signal) drop after 24 hours due to cell over confluence and death. 
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Supplemental Experimental Methods
Construct cloning
For the transient reporter analyses, PD-L1 and PD-L2 promoters were amplified by PCR from genomic DNA obtained from Jurkat cells using primers containing BglII and SacI restriction sites for the PD-L1 promoter, and Hind III for PD-L2, listed in Supplemental Table 1 . Generated fragments were cloned using standard methods (Sambrook et al., 1989) For the stable reporter cell lines, the PD-L1Prom-DSRed-FireflyLuciferase/Neo construct was generated by PCR amplification of the PD-L1 promoter from genomic DNA obtained from Jurkat cells, using primers containing EcoRI restriction sites listed in Supplemental Table 1 and then cloned into the MCS of the pGreen-Fire/Neo lentiviral plasmid vector (System Biosciences SBI, Mountain View, CA) to drive the expression of a GFP-T2A-Firefly luciferase cassette. GFP insert were substituted for the DsRedDR insert from the pDsRed-Express-DR vector plasmid (Clontech, Mountain View, CA) using the In-Fusion HD Cloning Kit (Clontech) according to the vendor manual for the product. We first amplified the DSRedDR fragment from the plasmid with the primers listed in Supplemental Table 1 . We then removed the GFP insert and linearized the lentivirus plasmid with BamHI-AgeI and then we carried out the infusion cloning. Positive clones were sequenced and DNA was prepared using the PureLink HiPure Filter Plasmid Maxiprep Kit (Invitrogen).
RNA sequencing (RNA-seq) Gene Set Enrichment and Transcription factor enrichment analysis.
RNA-seq data were generated using 2x100bp paired end sequencing using the Illumina HiSeq2000 platform. Paired end reads were mapped to the UCSC hg19 reference genome using Tophat2 (Kim et al. 2013) Normalized expression levels of genes were expressed in FPKM values as generated by cuffquant and cuffnorm. Both programs were run with the option "--frag-bias-correct" and "--multi-read-correct" to improve sensitivity. For differential gene expression call, a gene was defined as differentially expressed when its expression increased or decreased by at least 1.5 fold. RNA-seq runs on multiple sequencing lanes were independently mapped, and the expression values of each gene (in FPKM) were averaged across multiple lanes. To overcome noise in differential expression values caused by extremely low FPKM levels, we added a pseudo-FPKM value of 0.1 to all expression values.
The list of immune cell markers used in the analysis is included in Supplemental Table 4 .
Paired gene set enrichment analyses between patient-matched baseline and on-treatment samples were performed as described previously (Hugo et al. 2015) . We curated the interferon signatures from (Ribas et al. 2015, J. Clin. Oncol.,abstract) , the C2 CGP and C6 subsets from the Molecular Signature Database of the Broad Institute (Subramanian et al. 2005) . A list of genes used in the analysis is included in Supplemental Table 3 .
We collected transcription factor (TF) binding motifs in the form of position weight matrices (PWMs) from the JASPAR database (Mathelier et al. 2016) . Instead of using a fixed PWM score cutoff(s) as done in other PWM matching programs, we estimated the significance of the PWM score in a gene's promoter, which is defined as -1500 to +1500 bp from TSS, by comparing the score with a background distribution of the same PWM's scores on non-promoter regions from randomly selected genes. Specifically, we collected 10,000 random 3 KB intragenic regions (excluding the genes' promoter regions) and, for each sequence, computed the best score of a PWM. These scores defined an empirical background distribution of the PWM, and we defined a significant match of the PWM if and only if i) the PWM score was greater than or equal to the 95th percentile of the background PWM scores (i.e, P ≤ 0.05) and ii) a PWM score was at least 0.75 (the lowest cutoff in oPOSSUM). This approach avoided applying the same absolute PWM score cutoff on PWMs with differing lengths and complexities. To estimate enrichment of a TF's PWM W in a set of co-regulated genes G, we compared the number of significant matches of W in the promoter regions in G (accounting for possible multiple TSS for each gene) and the number of matches against a set of randomly selected promoter regions of the same size. We repeated the latter step 100,000 times to estimate the empirical enrichment P-value of the PWM. Finally, we corrected the PWM enrichment P-values across all tested PWMs for multiple hypothesis testing using the Benjamini-Hochberg (FDR) method. A TF's PWM was defined as enriched in a set of genes when its adjusted enrichment P-value was ≤ 0.05. Macrophage  CD2  CD5  NCAM1  CEACAM1  CCR1  ANPEP  CD33  CD68  CD3D CD19  KIR2DL4 CEACAM3  CCR3  CD164  CX3CR1  CD36  CD3E CD22  KIR3DL1 CEACAM5  CD44  FCER1A  CD14  ENG  CD3G MS4A1 KIR2DS4 CEACAM6  CD69  ITGAM  ITGAL  CD4  CD79A KIR3DL2 CEACAM8  PTGDR2  CD8A CD79B KLRB1  CSF3R  LAIR1  CD8B SDC1  KLRC1  FCGR2B  SIGLEC8  CD28 PTPRC  KLRC2  FCGR3A  CCR7  KLRK1  FCGR3B  IL2RA  KLRF1  SELL  NCR1  NCR2  NCR3  IL2RB  ITGA2  SIGLEC7  LY9  CD96  CD226   M1 macrophage  M2 macrophage  Dendritic cell  IL1B  CD163  CD86  IL12A  CSF1R  ITGAX  IL12B  IL10  CD83  HLA-DMA  MRC1  CSF2RB  HLA-DMB  IDO1  CD209  HLA-DOA  HLA-DOB  HLA-DPA1  HLA-DPB1  HLA-DQA1  HLA-DQA2  HLA-DQB1  HLA-DQB2  HLA-DRA  HLA-DRB1  HLA-DRB5 
